OncoMatch/Clinical Trials/NCT07397832
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Is NCT07397832 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chidamide and Rituximab for diffuse large b-cell lymphoma (dlbcl).
Treatment: Chidamide · Rituximab · Polatuzumab Vedotin · Chidamide Maintenance — A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive expression
CD20 positivity
Required: MYC positive expression
concurrent positive expression of C-MYC
Required: BCL2 positive expression
concurrent positive expression of Bcl-2
Performance status
ECOG 2–4(Completely disabled)
Demographics
Prior therapy
Cannot have received: Chidamide (Chidamide)
Prior treatment with Chidamide
Cannot have received: R-CHOP (R-CHOP)
Prior treatment with ... R-CHOP
Cannot have received: anthracycline
prior anthracycline therapy
Lab requirements
Blood counts
hb ≥90 g/l, anc ≥1.5 × 10⁹/l, plt ≥90 × 10⁹/l
Kidney function
cr ≤1.5 ×uln
Liver function
tbil ≤1.5 × uln; alt and ast ≤2.5 × uln (for patients with liver involvement: ≤5 × uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07397832 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD20?
Yes, CD20 positive expression is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC positive expression is a required biomarker for enrollment.
Does this trial require BCL2?
Yes, BCL2 positive expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify